Literature DB >> 9682354

Genetic variability among yellow fever virus 17D substrains.

R Galler1, P R Post, C N Santos, I I Ferreira.   

Abstract

The complete nucleotide sequence of the genome from two yellow fever (YF) virus strains, 17DD and 17D-213 was determined. Comparison of these sequences with those of other YF viruses, including the parental virulent Asibi strain, allowed the identification of 48 nucleotide sequence differences which are 17D strain-specific and potentially related to viral attenuation. Another 43 nucleotide sequence differences were not common to all 17D substrains and are therefore substrain specific. Of the 21 changes between 17DD and Asibi 15 only five led to amino acid substitutions whereas 13 substrain differences common to all 17D-204 substrains produced six amino acid substitutions. Since the exact passage histories of these viruses is known it was possible to calculate, for each strain, the number of accumulated changes per passage. Based on these data the 17DD strain was the most genetically stable virus.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9682354     DOI: 10.1016/s0264-410x(97)00278-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

Review 1.  The yellow fever 17D virus as a platform for new live attenuated vaccines.

Authors:  Myrna C Bonaldo; Patrícia C Sequeira; Ricardo Galler
Journal:  Hum Vaccin Immunother       Date:  2014-02-19       Impact factor: 3.452

2.  Development of a recombinant yellow fever vector expressing a HIV clade C founder envelope gp120.

Authors:  Jae-Sung Yu; Hua-Xin Liao; Jamie Pritchett; Cindy Bowman; Callie Vivian; Robert Parks; Shi-Mao Xia; Melissa Cooper; Wilton B Williams; Mattia Bonsignori; Steven G Reed; Meng Chen; Nathan Vandergrift; Charles M Rice; Barton F Haynes
Journal:  J Virol Methods       Date:  2017-08-31       Impact factor: 2.014

3.  The live-attenuated yellow fever vaccine 17D induces broad and potent T cell responses against several viral proteins in Indian rhesus macaques--implications for recombinant vaccine design.

Authors:  Philip A Mudd; Shari M Piaskowski; Patricia C Costa Neves; Richard Rudersdorf; Holly L Kolar; Christopher M Eernisse; Kim L Weisgrau; Marlon G Veloso de Santana; Nancy A Wilson; Myrna C Bonaldo; Ricardo Galler; Eva G Rakasz; David I Watkins
Journal:  Immunogenetics       Date:  2010-07-07       Impact factor: 2.846

Review 4.  Yellow fever: a reemerging threat.

Authors:  Christina L Gardner; Kate D Ryman
Journal:  Clin Lab Med       Date:  2010-03       Impact factor: 1.935

5.  Evolutionary dynamics of viral attenuation.

Authors:  Marty R Badgett; Alexandra Auer; Leland E Carmichael; Colin R Parrish; James J Bull
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

6.  Docking Studies of Adenosine Analogues with NS5 Methyltransferase of Yellow Fever Virus.

Authors:  Kh Dhanachandra Singh; Palani Kirubakaran; S Manikandaprabhu; S Nagamani; P Srinivasan; M Karthikeyan
Journal:  Indian J Microbiol       Date:  2011-08-09       Impact factor: 2.461

7.  Biological and immunological characterization of recombinant Yellow Fever 17D viruses expressing a Trypanosoma cruzi Amastigote Surface Protein-2 CD8+ T cell epitope at two distinct regions of the genome.

Authors:  Raquel T Nogueira; Alanderson R Nogueira; Mirian C S Pereira; Maurício M Rodrigues; Ricardo Galler; Myrna C Bonaldo
Journal:  Virol J       Date:  2011-03-18       Impact factor: 4.099

8.  Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil.

Authors:  Andréa Barbosa de Melo; Maria da Paz C da Silva; Maria Cecília F Magalhães; Laura Helena Vega Gonzales Gil; Eduardo M Freese de Carvalho; Ulisses M Braga-Neto; Giovani Rota Bertani; Ernesto T A Marques; Marli Tenório Cordeiro
Journal:  Am J Trop Med Hyg       Date:  2011-10       Impact factor: 2.345

Review 9.  Cross-species transfer of viruses: implications for the use of viral vectors in biomedical research, gene therapy and as live-virus vaccines.

Authors:  Derrick Louz; Hans E Bergmans; Birgit P Loos; Rob C Hoeben
Journal:  J Gene Med       Date:  2005-10       Impact factor: 4.565

10.  WHO Working Group on Technical Specifications for Manufacture and Evaluation of Yellow Fever Vaccines, Geneva, Switzerland, 13-14 May 2009.

Authors:  Morag Ferguson; Jinho Shin; Ivana Knezevic; Philip Minor; Alan Barrett
Journal:  Vaccine       Date:  2010-11-04       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.